Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

By Gwendolyn Wu • Sept. 30, 2026

Epilepsy R&D is breaking out of its old playbook

Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.

By Kelly Bilodeau • Sept. 29, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

By Alexandra Pecci • Sept. 25, 2026

Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

By PharmaVoice Staff • Sept. 25, 2026

A norovirus breakthrough?; another women’s healthtech haul

Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.

By PharmaVoice Staff • Sept. 18, 2026

A dark horse in the orexin race?

As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage asset it believes could have an edge over rivals.

By Meagan Parrish • Sept. 18, 2026

Sling banks $123M for an experimental thyroid eye disease pill

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

By Gwendolyn Wu • Sept. 17, 2026

8 biotech IPO prospects testing investor appetite

Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.

By Sy Mukherjee • Sept. 17, 2026

3 KRAS drugs to watch as the field expands

Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

By Kelly Bilodeau • Sept. 15, 2026

Cancer still dominates pharma R&D. Obesity is gaining ground.

Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.

By Alexandra Pecci • Sept. 11, 2026

Merck builds around Keytruda; prediction markets raise new risks

Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.

By PharmaVoice Staff • Sept. 11, 2026

mRNA cancer vaccines’ biggest barriers to market

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

By Alexandra Pecci • Sept. 10, 2026

5 questions that could determine Alzheimer’s next chapter

“The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

By Kelly Bilodeau • Sept. 9, 2026

FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders

After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said. 

By Kristin Jensen • Sept. 9, 2026

Gilead’s growing HIV franchise; cell therapy licensing deals plummet

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

By PharmaVoice Staff • Sept. 4, 2026

As measles outbreaks soar, where does drug R&D stand?

More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.

By Alexandra Pecci • Sept. 4, 2026

The hidden scale-out problem behind CAR-T’s growth

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.

By Sy Mukherjee • Sept. 1, 2026

Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

By Alexandra Pecci • Aug. 31, 2026

A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.

Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

By Meagan Parrish • Aug. 28, 2026

3 takeover targets in immunology

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

By Kelly Bilodeau • Aug. 26, 2026

Is AI finally proving its worth in drug R&D?

A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?

By Kelly Bilodeau • Aug. 26, 2026

Legend’s interim CEO sees a shorter path to the next era of CAR-T

Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.

By Sy Mukherjee • Aug. 25, 2026

Tyra’s one-drug, three-indication bet nears its first phase 2 test

What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.

By Alexandra Pecci • Aug. 21, 2026

Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.

By PharmaVoice Staff • Aug. 21, 2026

The scientific research pharma leaders keep sharing — and why

Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.

By Kelly Bilodeau • Aug. 20, 2026